Document is current

Article History

Received: 14 December 2022

Accepted: 25 February 2023

First Online: 24 March 2023

Declarations

:

: This study was conducted in accordance with ethical principles consistent with the Declaration of Helsinki and International Conference on Harmonisation (ICH), Good Clinical Practice, Good Pharmacoepidemiology Practice. All respondents explicitly agreed to participate in the NHWS and were provided fair-market value incentives for participation. The 2020 US NHWS was reviewed and approved by the Pearl Institutional Review Board (IRB; Indianapolis, IN, USA). Data were anonymized for use in this study and, as such, did not require further IRB approval.

: Not applicable.

: CD and TG are employees of Sunovion. XN was an employee of Sunovion at the time of this research. dM and KM are employees of Cerner Enviza, an Oracle company, which received funding from Sunovion to conduct this analysis. YZ is a postdoctoral research fellow at the Center for the Evaluation of Value and Risk in Health and at Sunovion.